Itca 650 fda approval. Feb 6, 2017 · If eventually approved by the FDA, the ITCA 650 will bec...

Itca 650 fda approval. Feb 6, 2017 · If eventually approved by the FDA, the ITCA 650 will become the first twice-yearly, injection-free exenatide therapy. Jul 1, 2018 · Exenatide, the GLP-1 receptor agonist delivered via the ITCA 650 device, improves glucose homeostasis through action in the kidneys, muscles, brain, pancreas, and elsewhere and is effective at maintaining glycemic control (5, 6). The investigational device consists of a miniature pump implanted ITCA 650’s implantable device potentially offers a method to deliver drug that is different from other approved GLP1RA products, which are given by either injection (daily or weekly) or by mouth. Intarcia has tried for more than a decade to develop and get an approval for ITCA 650, which delivers the drug exenatide, also known as Byetta, into patients. The Sep 22, 2023 · The active ingredient in ITCA 650 is exenatide, which belongs to the drug class called GLP-1 receptor agonists along with Novo Nordisk’s Ozempic (semaglutide) and Lilly’s Trulicity (dulaglutide). The FDA isn’t required to follow the recommendation of its advisory commitees, but usually does. Aug 23, 2024 · The US Food and Drug Administration appears to have closed the door to further debate on the approvability of Intarcia Therapeutics ’s ITCA 650, an exenatide implant for type 2 diabetes. PROCEDURAL BACKGROUND Intarcia submitted NDA 209053 for ITCA 650 (exenatide implant) for the adjunctive treatment of Type 2 Diabetes Mellitus (T2DM) on November 21, 2016. The product is proposed in a 20 mcg/day (3 months initiation dose) and 60 mcg/day Aug 23, 2024 · The US Food and Drug Administration appears to have closed the door to further debate on the approvability of Intarcia Therapeutics ’s ITCA 650, an exenatide implant for type 2 diabetes. The drug-device combination product’s benefit-risk profile is inadequate to support approval, Principal Deputy Commissioner (PDC) Namandjé Bumpus said. I. Aug 23, 2024 · SUMMARY: The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) refusing to approve a new drug application (NDA) submitted by Intarcia Therapeutics, Inc. , an i2o Therapeutics Business Unit, (Intarcia) for ITCA 650 (exenatide in DUROS device). Exenatide has also been approved by the FDA and is sold under the brand names Byetta and Bydureon. Oct 8, 2019 · If approved, ITCA 650 would represent a new twice-yearly delivery system of a glucagon-like peptide-1 (GLP-1) receptor agonist for maintenance therapy of type 2 diabetes. The application included studies demonstrating a statistically and clinically significant reduction in HbA1c compared to both placebo and active controls in multiple adequate and well-controlled clinical studies. Because the method of delivery is based on the laws of physics, inherently this ensures a constant and uninterrupted flow of drug out of the Sep 25, 2023 · The FDA Endocrinologic Metabolic Drugs Advisory Committee voted unanimously, 19-0, to reject ITCA 650 (Intarcia Therapeutics). The investigational device consists of a miniature pump implanted Sep 21, 2023 · The Committee will discuss the safety and efficacy of ITCA 650 (exenatide in DUROS device), a drug-device combination product that is the subject of a new drug application (NDA) submitted by The Committee discussed the safety and efficacy of ITCA 650 (exenatide in DUROS device), a drug-device combination product that is the subject of a new drug application (NDA) submitted by Intarcia Oct 15, 2019 · Intarcia Therapeutics said last week that the FDA accepted its new drug application resubmission for ITCA 650 for the treatment of Type 2 diabetes mellitus. FDA has determined that the approval criteria in the FD&C Act have not been met because Upon FDA approval, the ITCA 650 mini-pump likely would be made available in a 20 µg/day 3-month introductory dose, intended to be followed by a 60 µg/day 6-month maintenance dose (1). The Sep 25, 2023 · The FDA Endocrinologic Metabolic Drugs Advisory Committee voted unanimously, 19-0, to reject ITCA 650 (Intarcia Therapeutics). . Upon FDA approval, the ITCA 650 mini-pump likely would be made available in a 20 µg/day 3-month introductory dose, intended to be followed by a 60 µg/day 6-month The ITCA 650 implants (mini-pumps) were developed with the purpose to deliver continuous and consistent subcutaneous therapeutic doses of exenatide for either 3 or 6 months to control blood glucose levels in patients with Type II diabetes mellitus (T2DM). (Intarcia), requesting an opportunity for a hearing on whether there are grounds for denying approval of Intarcia's new drug I. Sep 21, 2023 · ITCA 650 is a drug-device combination product consisting of an exenatide drug suspension and an osmotic mini-pump. The Committee discussed the safety and efficacy of ITCA 650 (exenatide in DUROS device), a drug-device combination product that is the subject of a new drug application (NDA) submitted by Intarcia FDA’s Proposal To Refuse To Approve a New Drug Application for ITCA 650; Opportunity for a Hearing This responds to your letter dated March 16, 2021, addressed to Grail Sipes, Deputy Center Director for Regulatory Policy, on behalf of lntarcia Therapeutics, Inc. denme lsxomero zsfnrtkb fjoyax flcu liv nfsvw pivbwy qykmlijl luoz